BACKGROUND: Previous reports of suicide risk in patients with anxiety disorders have been inconsistent. METHODS: Using the FDA database, we assessed suicide and suicide attempt risk among patients, participating in recent clinical trials evaluating new anti-anxiety medications, with diagnosis of panic disorder (PD), social anxiety disorder or social phobia (SP), generalized anxiety disorder (GAD), post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD). RESULTS: Overall, among 20076 participating anxious patients, 12 committed suicide and 28 attempted suicide. The annual suicide risk rate was 193/100000 patients and annual suicide attempt risk was 1350/100000 patients. LIMITATIONS: Clinical trial data have limited applicability to clinical practice. Participants in clinical trials are a highly selected, nonrepresentative sample of the clinical population. A number of patients never complete clinical trials and thus data are based on a limited sub-sample. These trials were not primarily designed to assess suicide risk. CONCLUSIONS: Suicide risk in patients with anxiety disorders is higher than previously thought. Patients with anxiety disorders warrant explicit evaluation for suicide risk.
BACKGROUND: Previous reports of suicide risk in patients with anxiety disorders have been inconsistent. METHODS: Using the FDA database, we assessed suicide and suicide attempt risk among patients, participating in recent clinical trials evaluating new anti-anxiety medications, with diagnosis of panic disorder (PD), social anxiety disorder or social phobia (SP), generalized anxiety disorder (GAD), post traumatic stress disorder (PTSD), and obsessive compulsive disorder (OCD). RESULTS: Overall, among 20076 participating anxiouspatients, 12 committed suicide and 28 attempted suicide. The annual suicide risk rate was 193/100000 patients and annual suicide attempt risk was 1350/100000 patients. LIMITATIONS: Clinical trial data have limited applicability to clinical practice. Participants in clinical trials are a highly selected, nonrepresentative sample of the clinical population. A number of patients never complete clinical trials and thus data are based on a limited sub-sample. These trials were not primarily designed to assess suicide risk. CONCLUSIONS: Suicide risk in patients with anxiety disorders is higher than previously thought. Patients with anxiety disorders warrant explicit evaluation for suicide risk.
Authors: Sigal Zilcha-Mano; Kevin S McCarthy; Ulrike Dinger; Dianne L Chambless; Barbara L Milrod; Lauren Kunik; Jacques P Barber Journal: J Consult Clin Psychol Date: 2015-06-01
Authors: Glen T Schumock; Todd A Lee; Min J Joo; Robert J Valuck; Leslie T Stayner; Robert D Gibbons Journal: Drug Saf Date: 2011-07-01 Impact factor: 5.606
Authors: Jessica Bomyea; Ariel J Lang; Michelle G Craske; Denise Chavira; Cathy D Sherbourne; Raphael D Rose; Daniela Golinelli; Laura Campbell-Sills; Stacy S Welch; Greer Sullivan; Alexander Bystritsky; Peter Roy-Byrne; Murray B Stein Journal: Psychiatry Res Date: 2013-04-19 Impact factor: 3.222
Authors: David A Brent; Graham J Emslie; Greg N Clarke; Joan Asarnow; Anthony Spirito; Louise Ritz; Benedetto Vitiello; Satish Iyengar; Boris Birmaher; Neal D Ryan; Jamie Zelazny; Matthew Onorato; Betsy Kennard; Taryn L Mayes; Lynn L Debar; James T McCracken; Michael Strober; Robert Suddath; Henrietta Leonard; Giovanna Porta; Martin B Keller Journal: Am J Psychiatry Date: 2009-02-17 Impact factor: 18.112